All In Biotech

Drug Trial Radar · NCT07569081

A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome

A Randomized Phase 2/3, Double-blind, Placebo Controlled Adaptive Study Evaluating the Efficacy and Safety of Momelotinib in Participants With VEXAS Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 136 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

136

Planned (sponsor's estimate)

Start

Nov 2, 2026

Primary completion

Dec 19, 2028

Study completion Jun 17, 2031

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy and safety of momelotinib in participants with a diagnosis of VEXAS.

Conditions

  • VEXAS Syndrome

Interventions

  • MomelotinibDrug

    Momelotinib will be administered

  • GlucocorticoidsDrug

    Glucocorticoids (prednisone or prednisolone) will be administered

  • PlaceboDrug

    Placebo will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR (Objective response rate) at Week 26Time frame: At Week 26

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Salzburg, Austria

  • GSK Investigational Site

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.